Pulse Biosciences shares surge 38.79% intraday after positive nPulse cardiac catheter study results.

Pulse Biosciences surged 38.79% intraday after presenting robust clinical data for its nPulse Cardiac Catheter in treating atrial fibrillation. The company reported 100% procedural success at six months and 96% at one year in trials, with durable outcomes observed in a 150-patient European study. Positive results from late-breaking presentations at the 31st annual AF Symposium in Boston further reinforced confidence in the technology’s efficacy. The news, highlighting high procedural success rates and long-term effectiveness, aligns with the stock’s sharp intraday rally, driven by optimism around the device’s potential to address unmet needs in cardiac ablation therapies.